From penetrating solid tumors to new success rates for de novo design, the next wave of antibody therapies aims to transform the clinic.

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an ...

Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has been dosed in a Phase 1a/2a clinical trial ...

GAOXIN DISTRICT, BAOJI CITY, SHAANXI PROVINCE, CHINA, January 19, 2026 /EINPresswire.com/ -- Molybdenum plays a vital ...

Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.

Powder Alloy Development for Additive Manufacturing, AI for Material Allowables in Additive Manufacturing.

America Makes, Youngstown, Ohio, and the National Center for Defense Manufacturing and Machining (NCDMM) have announced two ...

Blue Gold's current fair value estimate is $47.83, but the stock trades near $4, due to severe legal and dilution risks. Read ...

New microbiome data show that intestinal bacteria can generate clinically relevant alcohol levels, validating a rare syndrome ...

In response, Blood Cancer UK, Lymphoma Action, and the stem cell charity Anthony Nolan have formally challenged the decision, citing serious concerns for patients who face "very limited alternatives".

Silicon carbide (SiC) kiln furniture, particularly reaction bonded silicon carbide (RBSIC/SiSiC) beams, has become a ...